. Author manuscript; available in PMC: 2019 Nov 15.

Published in final edited form as: Bioorg Med Chem. 2018 Oct 27;26(21):5751–5757. doi: 10.1016/j.bmc.2018.10.028

Table 2.

Percentage inhibition with 0.1 mM of inhibitor using Neu5Acα2–3GalβpNP as the sialidase substrate.

Sialidases	Neu5Ac2en (1)	Neu5Ac9N₃2en (2)	(TriazoleNeu5Ac2en)-A (6)	(TriazoleNeu5Ac2en)-AdE (7)	E-(TriazoleNeu5Ac2en)-AKE (8)
SpNanA	94.9 ± 2.2	78.6 ± 0.8	42.9 ± 2.4	61.9 ± 1.5	4.5 ± 2.1
SpNanB	2.7 ± 0.3	6.6 ± 2.1	8.8 ± 1.2	12.6 ± 1.8	9.7 ± 0.8
SpNanC	6.3 ± 1.6	13.4 ± 2.2	15.3 ± 2.1	13.5 ± 1.8	14.0 ± 3.0
V. cholerae	88.2 ± 0.6	86.0 ± 0.4	82.0 ± 3.0	85.8 ± 1.1	72.5 ± 0.9
A. ureafaciens	95.8 ± 0.6	99.2 ± 0.4	42.1 ± 3.5	95.7 ± 1.6	29.9 ± 1.3
C. perfringens	72.1 ± 0.0	57.1 ± 0.1	17.6 ± 1.3	48.9 ± 0.6	10.8 ± 2.1
BiNanH2	66.7 ± 1.7	49.4 ± 1.6	0.0 ± 0.3	3.3 ± 1.0	0.1 ± 5.0
PmST1	2.1 ± 0.8	1.7 ± 4.5	2.8 ± 0.2	0.1 ± 5.0	0.6 ± 2.5
hNEU2	74.9 ± 0.0	27.2 ± 1.2	12.2 ± 2.5	17.7 ± 0.8	0.2 ± 0.7